載入中
OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate (ADC) silicone dioxide linker technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Grasonville, Maryland.
收盤時
US$1.56
−US$0.06 · -3.70%
盤後
US$1.5685
+US$0.0085 · +0.54%
10月12日 下午7:56 ET
盤中時間採用ET。市場資料可能有所延遲。
OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate (ADC) silicone dioxide linker technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Grasonville, Maryland.
日內區間
目前US$1.56
52週區間
目前US$1.56
盤中時間採用ET。市場資料可能有所延遲。
OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate (ADC) silicone dioxide linker technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Grasonville, Maryland.
日內區間
目前US$1.56
52週區間
目前US$1.56
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 銷貨成本 | 36.31萬 USD | 2780 USD | 4220 USD | 805 USD | 115.96萬 USD |
| 毛利 | −36.31萬 USD | −2780 USD | −4220 USD | −805 USD | −115.96萬 USD |
| 研究與開發 | 163.61億 USD | 283.63萬 USD | 321.69萬 USD | 329.14萬 USD | 217.42萬 USD |
| 銷售、一般及管理費用 | 123.45億 USD | 397.48萬 USD | 112.06萬 USD | 115.37萬 USD | 150.35萬 USD |
| 營業費用 | 2834.26萬 USD | 681.11萬 USD | 434.26萬 USD | 444.63萬 USD | 367.77萬 USD |
| 利息收入 | 249 USD | — | — | — | — |
| 利息支出 | — | 205.18萬 USD | 344.89萬 USD | 180.84萬 USD | 258.29萬 USD |
| 折舊和攤銷 | 36.31萬 USD | 2780 USD | 4220 USD | 805 USD | 805 USD |
| 營業利益 | −2870.57萬 USD | −681.38萬 USD | −434.26萬 USD | −444.63萬 USD | −483.74萬 USD |
| 淨利 | −2875.38萬 USD | −888.29萬 USD | −779.16萬 USD | −625.47萬 USD | −742.02萬 USD |
公司資料更新於 2026年10月13日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
評級樣本有限，僅4項
報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI70.32萬0.00%2.3兆 USD0.03%US$381.22-0.19%
Vanguard Extended Market ETFVXF61.1萬0.00%954億 USD0.05%US$233.45-0.66%
iShares Micro-Cap ETFIWC18.2萬0.01%13.17億 USD0.60%US$181.87-0.62%
EA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSM7萬0.06%1.17億 USD0.73%US$15.86-0.50%Vanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFiShares Micro-Cap ETFIWCEA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSMAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
